Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/18636
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKolibianakis, E.en
dc.contributor.authorZikopoulos, K.en
dc.contributor.authorAlbano, C.en
dc.contributor.authorCamus, M.en
dc.contributor.authorTournaye, H.en
dc.contributor.authorVan Steirteghem, A.en
dc.contributor.authorDevroey, P.en
dc.date.accessioned2015-11-24T18:54:00Z-
dc.date.available2015-11-24T18:54:00Z-
dc.identifier.issn1472-6483-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18636-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectBody Mass Indexen
dc.subjectDrug Therapy, Combinationen
dc.subjectFemaleen
dc.subjectFertilization in Vitro/*methodsen
dc.subjectFollicle Stimulating Hormone/*administration & dosageen
dc.subjectGonadotropin-Releasing Hormone/*administration & dosage/*analogs &en
dc.subjectderivatives/antagonists & inhibitorsen
dc.subjectHormone Antagonists/*administration & dosageen
dc.subjectHormones/*administration & dosageen
dc.subjectHumansen
dc.subjectPolycystic Ovary Syndrome/*drug therapyen
dc.subjectPregnancyen
dc.subjectPregnancy Rateen
dc.subjectProspective Studiesen
dc.subjectSperm Injections, Intracytoplasmicen
dc.titleReproductive outcome of polycystic ovarian syndrome patients treated with GnRH antagonists and recombinant FSH for IVF/ICSIen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/14653891-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2003-
heal.abstractThe purpose of this prospective study was to assess the reproductive outcome of patients with polycystic ovarian syndrome (PCOS) treated by in-vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) with recombinant FSH (rFSH) and gonadotrophin releasing hormone (GnRH) antagonists. One hundred and ten patients were evaluated. The starting dose of rFSH was 100 IU in 67 women with body mass index (BMI) </=29 kg/m(2) and 200 IU in 43 women with BMI >29 kg/m(2). GnRH antagonist was started by the detection of a follicle of a 15mm in ultrasound scan. A significantly lower ongoing pregnancy rate per oocyte retrieval (25.6% versus 46.7%, P = 0.04) and a higher occurrence of ovarian hyperstimulation syndrome (16.3% versus 3.0%, P = 0.03) was observed in the group of patients with BMI >29 kg/m(2) as compared with the group of patients with BMI </=29 kg/m(2), respectively. In conclusion, in GnRH antagonist cycles a worse reproductive outcome is expected in PCOS patients with BMI >29 kg/m(2) in whom stimulation is initiated with 200 IU of rFSH as compared with PCOS patients with BMI </=29 kg/m(2) in whom stimulation is initiated with 100 IU of rFSH.en
heal.journalNameReprod Biomed Onlineen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons